Integra LifeSciences Holdings Corporation
NASDAQ•IART
CEO: Dr. Stuart M. Essig Ph.D.
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 1995-08-16
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Contact Information
Market Cap
$822.54M
P/E (TTM)
-1.6
30
Dividend Yield
--
52W High
$24.37
52W Low
$9.96
52W Range
Rank46Top 59.5%
3.5
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$434.93M+0.00%
4-Quarter Trend
EPS
-$0.02+0.00%
4-Quarter Trend
FCF
-$37.25M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Revenue Growth Despite Issues Total revenue reached $1.64B, up 1.5% for 2025, primarily driven by Acclarent sales integration despite quality issues.
Strategic Acquisition Integration Completed Acclarent ENT portfolio acquisition in Q2 2024, enhancing Codman Specialty Surgical segment positioning globally.
Durepair Rights Secured Secured Durepair dura substitute rights in October 2024 for $45.0M cash consideration, bolstering TT segment.
Strong Year-End Liquidity Year-end cash and equivalents totaled $235.0M, supported by strong liquidity management across foreign operations.
Risk Factors
Major Goodwill Impairment Reported net loss of $(516.5)M, heavily impacted by $511.4M goodwill impairment charge recorded in Q2 2025.
Gross Margin Contraction Gross margin decreased to 50.9% from 54.8% due to quality issues, higher costs, and tariff impacts across segments.
FDA Regulatory Scrutiny Multiple FDA warning letters received for quality systems; remediation efforts ongoing, potentially disrupting production timelines.
Macroeconomic Uncertainty Risks Continuing global macroeconomic uncertainty, tariffs, and geopolitical instability pose risks to demand and supply chain stability.
Outlook
Braintree Facility Operationalization Plan to operationalize new Braintree manufacturing facility by first half of 2026 to consolidate production efforts effectively.
DuraSorb PMA Approval Anticipate securing PMA approval for DuraSorb in 2026 for implant-based breast reconstruction indications.
Restructuring for Resilience Approved restructuring initiative expecting $12.6M aggregate costs through 2026 to improve supply chain resilience.
Executive Severance Plan Executive Severance Pay Plan adopted in February 2026 to support talent retention and leadership continuity efforts.
Peer Comparison
Revenue (TTM)
$2.84B
$1.64B
$1.37B
Gross Margin (Latest Quarter)
87.7%
78.3%
70.5%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| PRAX | $6.73B | -23.6 | -58.7% | 0.0% |
| ESTA | $2.07B | -41.3 | -201.8% | 0.8% |
| TNDM | $1.62B | -7.9 | -142.0% | 64.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
4.4%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow
Deep Research
Next earnings:Apr 29, 2026
EPS:$0.40
|Revenue:$381.81M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data